Neurology-Neuroimmunology & Neuroinflammation

Article	Citations
Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes	313
Guillain-Barré syndrome related to COVID-19 infection	268
Guillain-Barré syndrome: The first documented COVID-19–triggered autoimmune neurologic disease	183
COVID-19-related acute necrotizing encephalopathy with brain stem involvement in a patient with aplastic anemia	154
Acute disseminated encephalomyelitis after SARS-CoV-2 infection	151
COVID-19 outcomes in MS	127
Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology	115
Neurologic syndromes related to anti-GAD65	105
Anti–SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome	104
Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID	100
COVID-19-associated acute necrotizing myelitis	99
COVID-19 and MS disease-modifying therapies	84
Guillain-Barré syndrome related to SARS-CoV-2 infection	82
Acute Disseminated Encephalomyelitis and Acute Hemorrhagic Leukoencephalitis Following COVID-19	82
Neurosarcoidosis	78
Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes	72
Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders	71
Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France	71
International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis	67
COVID-19 Among Patients With Multiple Sclerosis	67
Clinical and imaging features of children with autoimmune encephalitis and MOG antibodies	66
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19	65
Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders	65
Single-cell RNA-seq analysis of human CSF microglia and myeloid cells in neuroinflammation	64
Increased CSF levels of IL-1β, IL-6, and ACE in SARS-CoV-2–associated encephalitis	61

Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis	60
COVID-19 infection in a patient with multiple sclerosis treated with fingolimod	60
Serum biomarkers in myelin oligodendrocyte glycoprotein antibody–associated disease	59
Overlapping central and peripheral nervous system syndromes in MOG antibody–associated disorders	58
Rituximab, MS, and pregnancy	58
COVID-19-associated ophthalmoparesis and hypothalamic involvement	58
Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies	57
Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder	54
Clinical and MRI phenotypes of sarcoidosis-associated myelopathy	54
Clinical significance of Kelch-like protein 11 antibodies	54
COVID-19—White matter and globus pallidum lesions	53
COVID-19 Severity in Multiple Sclerosis	53
CNS inflammatory vasculopathy with antimyelin oligodendrocyte glycoprotein antibodies in COVID-19	52
Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis	51
Presentations and mechanisms of CNS disorders related to COVID-19	51
Dysregulation of the Adaptive Immune System in Patients With Early-Stage Parkinson Disease	49
Retinal Optical Coherence Tomography in Neuromyelitis Optica	45
IgG4-Mediated Neurologic Autoimmunities	44
Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders	44
Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis	43
Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder	43
Immune profiling of plasma-derived extracellular vesicles identifies Parkinson disease	43
Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G in the CSF	43
Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?	43
Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression	42
Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis	42
Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis	42
Plasma Markers of Neurologic Injury and Inflammation in People With Self-Reported Neurologic Postacute Sequelae of SARS-CoV-2 Infection	41
New BBB Model Reveals That IL-6 Blockade Suppressed the BBB Disorder, Preventing Onset of NMOSD	41
Long-term Functional Outcomes and Relapse of Anti-NMDA Receptor Encephalitis	41
HLA association in MOG-IgG– and AQP4-IgG–related disorders of the CNS in the Dutch population	41
Anti-CD20 therapies and pregnancy in neuroimmunologic disorders	41
Pediatric autoimmune encephalitis	40
Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS	38
The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy	37
Altered fovea in AQP4-IgG–seropositive neuromyelitis optica spectrum disorders	37
Seizure-related 6 homolog like 2 autoimmunity	36
Chitinases and chitinase-like proteins as biomarkers in neurologic disorders	36
Hypogammaglobulinemia and Infections in Patients With Multiple Sclerosis Treated With Rituximab	36
Discontinuation of Immunosuppressive Therapy in Patients With Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies	35
Treatment and outcome of aquaporin-4 antibody–positive NMOSD	35
Anti-IgLON5 Disease	35
Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti–SARS-CoV-2 Antibodies	34
Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis	34
Encephalopathies Associated With Severe COVID-19 Present Neurovascular Unit Alterations Without Evidence for Strong Neuroinflammation	34
COVID-19 in MS	33
Plasma Biomarkers of Neuropathogenesis in Hospitalized Patients With COVID-19 and Those With Postacute Sequelae of SARS-CoV-2 Infection	33
Cladribine vs other drugs in MS	32
Leveraging Visual Outcome Measures to Advance Therapy Development in Neuroimmunologic Disorders	32
Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder	32

Recent cannabis use in HIV is associated with reduced inflammatory markers in CSF and blood	31
Gene-Environment Interactions in Multiple Sclerosis	31
Pregnancy outcomes in anti-NMDA receptor encephalitis	30
Increased Serum Neurofilament Light and Thin Ganglion Cell–Inner Plexiform Layer Are Additive Risk Factors for Disease Activity in Early Multiple Sclerosis	30
Inflammatory profiles relate to survival in subtypes of amyotrophic lateral sclerosis	30
Risk of Getting COVID-19 in People With Multiple Sclerosis	30
Targeting B Cells to Modify MS, NMOSD, and MOGAD	30
Longitudinally Extensive Myelitis Associated With Immune Checkpoint Inhibitors	30
Population-Based Epidemiology Study of Paraneoplastic Neurologic Syndromes	30
Transfer of monoclonal antibodies into breastmilk in neurologic and non-neurologic diseases	30
Microglia Activation in Basal Ganglia Is a Late Event in Huntington Disease Pathophysiology	29
Safety of potential breast milk exposure to IFN-β or glatiramer acetate	29
Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD	29
Tailoring B cell depletion therapy in MS according to memory B cell monitoring	28
Ocrelizumab initiation in patients with MS	28
Incidence and Impact of COVID-19 in MS	28
Kappa-Free Light Chains in CSF Predict Early Multiple Sclerosis Disease Activity	28
Systemic Inflammation Is Associated With Neurologic Involvement in Pediatric Inflammatory Multisystem Syndrome Associated With SARS-CoV-2	28
Rituximab-Induced Hypogammaglobulinemia and Infections in AQP4 and MOG Antibody–Associated Diseases	27
COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis	27
Infliximab treatment in pathology-confirmed neurosarcoidosis	27
Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children	26
Amyotrophic Lateral Sclerosis Survival Associates With Neutrophils in a Sex-specific Manner	26
Insights into disseminated MS brain pathology with multimodal diffusion tensor and PET imaging	26
Thymoma and Autoimmune Encephalitis	26
Antiparanodal antibodies and IgG subclasses in acute autoimmune neuropathy	26
Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis	26
Exercise Diminishes Plasma Neurofilament Light Chain and Reroutes the Kynurenine Pathway in Multiple Sclerosis	26
High serum neurofilament associates with diffuse white matter damage in MS	26
Clostridium bolteae is elevated in neuromyelitis optica spectrum disorder in India and shares sequence similarity with AQP4	26
SARS-CoV-2 Infection in Multiple Sclerosis	25
CSF Findings in Acute NMDAR and LGI1 Antibody–Associated Autoimmune Encephalitis	25
Acute Inflammatory Diseases of the Central Nervous System After SARS-CoV-2 Vaccination	25
Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy	25
Cortical Thickness and Serum NfL Explain Cognitive Dysfunction in Newly Diagnosed Patients With Multiple Sclerosis	25
Risk of MS relapse after yellow fever vaccination	25
Targeting B cells to modify MS, NMOSD, and MOGAD	25
Aryl Hydrocarbon Receptor Activation in Astrocytes by Laquinimod Ameliorates Autoimmune Inflammation in the CNS	25
Microglia as Central Protagonists in the Chronic Stress Response	25
Long-term prognostic value of longitudinal measurements of blood neurofilament levels	25
Serum neurofilament light chain	25
Monitoring of radiologic disease activity by serum neurofilaments in MS	24
Neurosarcoidosis	24
Toward Precision Phenotyping of Multiple Sclerosis	24
Clinical and Radiologic Disease Activity in Pregnancy and Postpartum in MS	24
Dimethyl Fumarate Reduces Inflammation in Chronic Active Multiple Sclerosis Lesions	24
Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis	24
Interleukin-26, preferentially produced by T H 17 lymphocytes, regulates CNS barrier function	24
Inflammatory and stress markers predicting pneumonia, outcome, and etiology in patients with stroke	24
Vaccine Hesitancy in Patients With Multiple Sclerosis	24
Updated Results of the COVID-19 in MS Global Data Sharing Initiative	24
Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS	23
Effects of Vitamin D and Body Mass Index on Disease Risk and Relapse Hazard in Multiple Sclerosis	23
COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients	23
Imaging Characteristics of Choroid Plexuses in Presymptomatic Multiple Sclerosis	23
Potential Role of CHI3L1+ Astrocytes in Progression in MS	23
Recovery From COVID-19 in Multiple Sclerosis	23
Abnormal B-Cell and Tfh-Cell Profiles in Patients With Parkinson Disease	22
Temporal Dynamics of MOG Antibodies in Children With Acquired Demyelinating Syndrome	22
Autoimmune Encephalitis Resembling Dementia Syndromes	22
Neuroprotective Properties of 4-Aminopyridine	22
Differential expression of the T-cell inhibitor TIGIT in glioblastoma and MS	22
Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab	21
Gut microbiota composition is associated with narcolepsy type 1	21
Primary Angiitis of the CNS	21
CSF chitinase 3-like-1 association with disability of primary progressive MS	21
Chronic demyelination exacerbates neuroaxonal loss in patients with MS with unilateral optic neuritis	21
Neurological Autoimmunity Associated With Homer-3 Antibody	21
Clinically based score predicting cryptogenic NORSE at the early stage of status epilepticus	21
Presence of SARS-CoV-2 Transcripts in the Choroid Plexus of MS and Non-MS Patients With COVID-19	21
RNA-binding protein altered expression and mislocalization in MS	21
Clinical Features of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorders	21
Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic Models	21
Bickerstaff brainstem encephalitis with or without anti-GQ1b antibody	21
B-Cell Compartmental Features and Molecular Basis for Therapy in Autoimmune Disease	21
High-throughput investigation of molecular and cellular biomarkers in NMOSD	20
Direct economic burden of patients with autoimmune encephalitis in western China	20
Ocrelizumab shorter infusion	20
MRI Characteristics of Autoimmune Encephalitis With Autoantibodies to GABAA Receptor	20
Heterogeneity of Acetylcholine Receptor Autoantibody–Mediated Complement Activity in Patients With Myasthenia Gravis	20

Progranulin Suppressed Autoimmune Uveitis and Autoimmune Neuroinflammation by Inhibiting Th1/Th17 Cells and Promoting Treg Cells and M2 Macrophages	20
Gut bacteria Akkermansia elicit a specific IgG response in CSF of patients with MS	20
Serum neurofilament light chain and optical coherence tomography measures in MS	20
Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder	20
Brain amyloid in virally suppressed HIV-associated neurocognitive disorder	20
Decrease in Serum Anti-MAG Autoantibodies Is Associated With Therapy Response in Patients With Anti-MAG Neuropathy	20
Guillain-Barré Syndrome Outbreak in Peru 2019 Associated With Campylobacter jejuni Infection	20
Predicting Aggressive Multiple Sclerosis With Intrathecal IgM Synthesis Among Patients With a Clinically Isolated Syndrome	20